NuVasive, Inc. (NUVA)
(Delayed Data from NSDQ)
$62.96 USD
+0.74 (1.19%)
Updated May 3, 2019 04:00 PM ET
After-Market: $62.96 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$62.96 USD
+0.74 (1.19%)
Updated May 3, 2019 04:00 PM ET
After-Market: $62.96 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
NuVasive Launches Titanium Spine Implant Modulus TLIF-O
by Zacks Equity Research
The launch of Modulus TLIF-O is expected to boost the AMS portfolio of NuVasive (NUVA).
Why Is NuVasive (NUVA) Down 3.9% Since Last Earnings Report?
by Zacks Equity Research
NuVasive (NUVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain NuVasive (NUVA) Stock for Now
by Zacks Equity Research
Investor confidence in the stock is high on NuVasive's (NUVA) sturdy spine business.
VREX vs. NUVA: Which Stock Is the Better Value Option?
by Zacks Equity Research
VREX vs. NUVA: Which Stock Is the Better Value Option?
NuVasive (NUVA) Q1 Earnings Top Estimates, Margins Strong
by Zacks Equity Research
NuVasive's (NUVA) solid international sales in Q1 boost investor confidence in the stock.
NuVasive (NUVA) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
NuVasive (NUVA) delivered earnings and revenue surprises of 29.27% and 2.21%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
NuVasive (NUVA) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
NuVasive (NUVA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NuVasive (NUVA) Completes First COHERE XLIF Case in U.S.
by Zacks Equity Research
NuVasive's (NUVA) Advanced Materials Science implant portfolio will be fortified by the incorporation of the Porous PEEK technology into its implants for lateral single-position surgery.
NuVasive (NUVA) Down 1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
NuVasive (NUVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
NuVasive (NUVA) Q4 Earnings Beat Estimates, Margins Fall
by Zacks Equity Research
NuVasive (NUVA) reports growth in revenues across all key operating segments in the fourth quarter of 2018.
NuVasive (NUVA) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
NuVasive (NUVA) delivered earnings and revenue surprises of 9.52% and 0.01%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
NuVasive (NUVA) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
NuVasive (NUVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Solid Global Business Aids NuVasive Amid Pricing Pressure
by Zacks Equity Research
Per NuVasive (NUVA), the international region holds significant growth opportunity. However, pricing pressure is a major headwind.
NuVasive's Monolith Corpectomy System Ok'd for Expanded Use
by Zacks Equity Research
NuVasive's (NUVA) latest FDA 510 (k) clearance receipt is expected to augment customer base and market reach.
NuVasive (NUVA) Up 11% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
NuVasive (NUVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
NuVasive Porous PEEK Implant OK'd for Use in XLIF Procedure
by Zacks Equity Research
NuVasive (NUVA) adopts initiatives to boost the U.S. Spinal Hardware unit.
Bear of the Day: NuVasive (NUVA)
by Kevin Cook
Another earnings hiccup puts this spinal surgery innovator back in the cellar of the Zacks Rank
NuVasive (NUVA) Q3 Earnings Lag Estimates, Revenues Top Mark
by Zacks Equity Research
NuVasive (NUVA) registers balanced growth across its couple of business wings.
NuVasive (NUVA) Q3 Earnings Miss Estimates
by Zacks Equity Research
NuVasive (NUVA) delivered earnings and revenue surprises of -11.11% and 2.12%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
NuVasive (NUVA) Q3 Earnings Preview: What's Shaping Up?
by Zacks Equity Research
NuVasive (NUVA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is NuVasive (NUVA) Up 8.3% Since Last Earnings Report?
by Zacks Equity Research
NuVasive (NUVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
NuVasive (NUVA) Q2 Earnings Meet Estimates, EPS View Down
by Zacks Equity Research
NuVasive (NUVA) expects robust demand for recently-launched products and positive surgeon conversion efforts as its new Lateral Single-Position Surgery procedure gains traction in the market.
NuVasive (NUVA) Q2 Earnings Match Estimates
by Zacks Equity Research
NuVasive (NUVA) delivered earnings and revenue surprises of 0.00% and 2.00%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
NuVasive (NUVA) in Focus: Stock Moves 6.02% Higher
by Zacks Equity Research
NuVasive (NUVA) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Medical Product Stock Earnings on Jul 31: HOLX, NUVA, QSII
by Zacks Equity Research
Let's take a look at the factors that are likely to influence the earnings results of a few MedTech bigwigs within the broader Medical universe.